Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – Research analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for Fennec Pharmaceuticals in a report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of $0.17 for the quarter, down from their previous forecast of $0.26. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2026 earnings at $0.22 EPS, Q3 2027 earnings at $0.36 EPS, Q4 2027 earnings at $0.42 EPS and FY2027 earnings at $1.33 EPS.
Separately, B. Riley Financial upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the stock currently has an average rating of “Strong Buy”.
Fennec Pharmaceuticals Price Performance
Shares of FRX opened at C$8.33 on Tuesday. The firm’s 50 day moving average is C$10.53 and its 200-day moving average is C$11.11. The stock has a market capitalization of C$284.58 million, a P/E ratio of -23.80 and a beta of 3.01. Fennec Pharmaceuticals has a 12-month low of C$7.02 and a 12-month high of C$13.83.
Insider Transactions at Fennec Pharmaceuticals
In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov sold 10,349 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of C$10.69, for a total value of C$110,630.81. Following the transaction, the director directly owned 2,709,294 shares of the company’s stock, valued at C$28,962,352.86. The trade was a 0.38% decrease in their position. 16.20% of the stock is owned by company insiders.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
See Also
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
